We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Funding that library

2 June 2009 By Robert Cyran

The IrishAmerican biotech faces a 2011 cash crunch. So selling a minority stake, to Pfizer or Bristol, makes sense given its intriguing but unfunded drugs pipeline. Moreover, the wave of pharma consolidation could hinder a full sale.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)